Literature DB >> 10623528

Three-dimensional structure of M. tuberculosis dihydrofolate reductase reveals opportunities for the design of novel tuberculosis drugs.

R Li1, R Sirawaraporn, P Chitnumsub, W Sirawaraporn, J Wooden, F Athappilly, S Turley, W G Hol.   

Abstract

Dihydrofolate reductase (DHFR) catalyzes the NADPH-dependent reduction of dihydrofolate to tetrahydrofolate and is essential for the synthesis of thymidylate, purines and several amino acids. Inhibition of the enzyme's activity leads to arrest of DNA synthesis and cell death. The enzyme has been studied extensively as a drug target for bacterial, protozoal and fungal infections, and also for neoplastic and autoimmune diseases. Here, we report the crystal structure of dihydrofolate reductase from Mycobacterium tuberculosis, a human pathogen responsible for the death of millions of human beings per year. Three crystal structures of ternary complexes of M. tuberculosis DHFR with NADP and different inhibitors have been determined, as well as the binary complex with NADP, with resolutions ranging from 1.7 to 2.0 A. The three DHFR inhibitors are the anticancer drug methotrexate, the antimicrobial trimethoprim and Br-WR99210, an analogue of the antimalarial agent WR99210. Structural comparison of these complexes with human dihydrofolate reductase indicates that the overall protein folds are similar, despite only 26 % sequence identity, but that the environments of both NADP and of the inhibitors contain interesting differences between the enzymes from host and pathogen. Specifically, residues Ala101 and Leu102 near the N6 of NADP are distinctly more hydrophobic in the M. tuberculosis than in the human enzyme. Another striking difference occurs in a region near atoms N1 and N8 of methotrexate, which is also near atom N1 of trimethoprim, and near the N1 and two methyl groups of Br-WR99210. A glycerol molecule binds here in a pocket of the M. tuberculosis DHFR:MTX complex, while this pocket is essentially filled with hydrophobic side-chains in the human enzyme. These differences between the enzymes from pathogen and host provide opportunities for designing new selective inhibitors of M. tuberculosis DHFR. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10623528     DOI: 10.1006/jmbi.1999.3328

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  40 in total

1.  NMR-based solution structure of the complex of Lactobacillus casei dihydrofolate reductase with trimethoprim and NADPH.

Authors:  Vladimir I Polshakov; Eugeni G Smirnov; Berry Birdsall; Geoff Kelly; James Feeney
Journal:  J Biomol NMR       Date:  2002-09       Impact factor: 2.835

2.  Role of mutations in dihydrofolate reductase DfrA (Rv2763c) and thymidylate synthase ThyA (Rv2764c) in Mycobacterium tuberculosis drug resistance.

Authors:  Claudio U Köser; Richard N Veerapen-Pierce; David K Summers; John A C Archer
Journal:  Antimicrob Agents Chemother       Date:  2010-10       Impact factor: 5.191

3.  Charged Nonclassical Antifolates with Activity Against Gram-Positive and Gram-Negative Pathogens.

Authors:  Eric Scocchera; Stephanie M Reeve; Santosh Keshipeddy; Michael N Lombardo; Behnoush Hajian; Adrienne E Sochia; Jeremy B Alverson; Nigel D Priestley; Amy C Anderson; Dennis L Wright
Journal:  ACS Med Chem Lett       Date:  2016-05-05       Impact factor: 4.345

4.  Drugging the Folate Pathway in Mycobacterium tuberculosis: The Role of Multi-targeting Agents.

Authors:  Behnoush Hajian; Eric Scocchera; Carolyn Shoen; Jolanta Krucinska; Kishore Viswanathan; Narendran G-Dayanandan; Heidi Erlandsen; Alexavier Estrada; Katarína Mikušová; Jana Korduláková; Michael Cynamon; Dennis Wright
Journal:  Cell Chem Biol       Date:  2019-03-28       Impact factor: 8.116

5.  Design of novel antituberculosis compounds using graph-theoretical and substructural approaches.

Authors:  Alejandro Speck Planche; Marcus Tulius Scotti; América García López; Vicente de Paulo Emerenciano; Enrique Molina Pérez; Eugenio Uriarte
Journal:  Mol Divers       Date:  2009-04-02       Impact factor: 2.943

6.  para-Aminosalicylic acid is a prodrug targeting dihydrofolate reductase in Mycobacterium tuberculosis.

Authors:  Jun Zheng; Eric J Rubin; Pablo Bifani; Vanessa Mathys; Vivian Lim; Melvin Au; Jichan Jang; Jiyoun Nam; Thomas Dick; John R Walker; Kevin Pethe; Luis R Camacho
Journal:  J Biol Chem       Date:  2013-06-18       Impact factor: 5.157

7.  Identification of P218 as a potent inhibitor of Mycobacterium ulcerans DHFR.

Authors:  Gustavo P Riboldi; Rachael Zigweid; Peter J Myler; Stephen J Mayclin; Rafael M Couñago; Bart L Staker
Journal:  RSC Med Chem       Date:  2020-10-22

8.  Kinetic and structural characterization of dihydrofolate reductase from Streptococcus pneumoniae.

Authors:  Jeeyeon Lee; Neela H Yennawar; Jongsik Gam; Stephen J Benkovic
Journal:  Biochemistry       Date:  2010-01-12       Impact factor: 3.162

9.  MixMD Probeview: Robust Binding Site Prediction from Cosolvent Simulations.

Authors:  Sarah E Graham; Noah Leja; Heather A Carlson
Journal:  J Chem Inf Model       Date:  2018-06-26       Impact factor: 4.956

10.  Design and Synthesis of a Focused Library of Diamino Triazines as Potential Mycobacterium tuberculosis DHFR Inhibitors.

Authors:  Arundhati C Lele; Archana Raju; Mihir P Khambete; M K Ray; M G R Rajan; Manisha A Arkile; Nandadeep J Jadhav; Dhiman Sarkar; Mariam S Degani
Journal:  ACS Med Chem Lett       Date:  2015-10-17       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.